
For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will …

Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …

Alex Azar is officially President Trump’s nominee for the position as head of the Health and Human Services (HHS) agency, …
Swedish biopharma firm Hansa Medical broke tragic and unexpected news in November when it announced the death of its CEO …

With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 …

US drug maker Mylan has announced its intention to withdraw from the Tel Aviv Stock Exchange (TASE), ending its involvement …

Novartis posted strong results for its wet age-related macular degeneration (AMD) drug, by showing superiority against Eylea in Phase 3 …

Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …

A recent report by the OECD shares concerns that the UK’s overall health looks set to face a crisis due …

Nigeria’s drug regulatory body has fiercely countered claims made by Chief Economist of PwC in West Africa, Andrew Nevin, that …

Dynavax had said it was the last throw of the dice for its hepatitis B vaccine, Hepislav-B – the data …

Sanofi has decided to build its pipeline in neurological disorders with the agreement to develop Principia Biopharma’s BTK inhibitor candidate …

New findings from the Early Breast Cancer Trialists’ Collaborative Group have demonstrated that oestrogen receptor-positive (ER-positive) breast cancer is able …

Sage Therapeutics share price soared 50% on the release that its two Phase 3 trials of brexanolone showed statistically significant …

A young child has been brought back from the verge of death after an experimental combination of stem cell and …